Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection (UTI-cIAI)
26 июня 2026 г. обновлено: Xianqiang Chen, Fujian Medical University Union Hospital
A Single-Center Randomized Controlled Pilot Study on the Effect of Ulinastatin on Systemic Immune and Inflammatory Response in Patients With Complicated Intra-Abdominal Infection
Complicated intra-abdominal infection (cIAI) triggers dysregulated systemic inflammation and immune paralysis leading to high organ failure and death risk.
Ulinastatin is a protease inhibitor with anti-inflammatory properties, but its dose-related effects on immune-inflammation of cIAI patients remain unclear.
This single-center single-blinded three-arm randomized controlled pilot study enrolls adult cIAI patients (≥18 years, SOFA≥2) at Fujian Medical University Union Hospital.
Eligible patients are randomized into low-dose ulinastatin, high-dose ulinastatin and normal saline placebo groups (1:1:1, 5 days intravenous treatment plus standard care), total planned enrollment 165 participants after 10% dropout adjustment.
Primary endpoint is Day5 change of Systemic Immune-Inflammation Index (SII); secondary outcomes include serial inflammatory biomarkers, SOFA variation, organ dysfunction, hospitalization duration, 28-day mortality and safety profiles.
This pilot aims to clarify ulinastatin's immune-modulating effect and inform future large RCT design.
Обзор исследования
Статус
Еще не набирают
Условия
Вмешательство/лечение
Подробное описание
This is a single-center, randomized, single-blind, three-arm parallel-group superiority pilot clinical trial performed at Fujian Medical University Union Hospital. Randomization sequence is generated with SAS 9.3 software, and random grouping is implemented by sealed envelope method at a 1:1:1 allocation ratio (low-dose ulinastatin : high-dose ulinastatin : normal saline control =1:1:1). A total of 165 participants are planned, with 55 subjects in each group after accounting for an anticipated 10% dropout rate.
All enrolled patients are adults aged ≥18 years diagnosed with complicated intra-abdominal infection (cIAI) within 48 hours, confirmed by clinical manifestation, laboratory tests and abdominal imaging, accompanied by SOFA score ≥2. Subjects with severe immunodeficiency, end-stage liver or renal disease, malignancy, pregnancy, hypersensitivity to ulinastatin and other severe comorbidities are excluded. Written informed consent is obtained prior to any study-related procedures.
All participants receive standardized routine management including surgical source control, antibacterial therapy and organ function supportive treatment. Intervention regimens last for consecutive 5 days via intravenous drip: low-dose group receives ulinastatin 100,000 IU three times daily diluted in 100 mL normal saline; high-dose group receives ulinastatin 300,000 IU three times daily diluted in 100 mL normal saline; control group receives equal volume of sterile normal saline three times daily as placebo. For patients with progressive organ dysfunction after 24-48 hours without improvement, rescue high-dose ulinastatin is allowed per investigator's clinical judgment.
Primary endpoint is the absolute change of Systemic Immune-Inflammation Index (SII) from baseline to treatment Day 5. Secondary endpoints include dynamic changes of CRP, PCT, IL-6, NLR, PLR, LMR, CLR, CD4⁺/CD8⁺ T cell counts at Days 1,3,5 and 7; sequential SOFA score changes; cumulative incidence of new organ failure within 7 and 14 days; ICU and total hospital stay duration; reoperation rate, secondary infection rate, in-hospital and 28-day all-cause mortality. Subgroup analyses are preset stratified by operation type, pathogenic bacteria (multidrug-resistant pathogen or candidiasis) and baseline disease severity (MPI/SOFA score).
All adverse events (AEs) from informed consent to 4 weeks after final study medication are documented following CTCAE Version 5.0. All serious adverse events (SAEs) must be reported to the sponsor (Techpool Bio-Pharma Co., Ltd.) within 24 hours. Study will be prematurely terminated if excessive unexpected severe adverse events occur or interim analysis demonstrates no meaningful intergroup difference in primary inflammatory markers. Study monitoring, source document verification and data management are conducted in accordance with GCP and Declaration of Helsinki principles.
Тип исследования
Интервенционный
Регистрация (Оцененный)
165
Фаза
- Непригодный
Контакты и местонахождение
В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.
Места учебы
-
-
Fujian
-
Fuzhou, Fujian, Китай, 350001
- Fujian Medical University Union Hospital
-
Контакт:
- JunRong Zhang, MD
- Номер телефона: 0591-83357896
- Электронная почта: foxbaby34@163.com
-
Главный следователь:
- QinYong Weng, MD
-
Младший исследователь:
- XianQiang Chen, MD
-
-
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Нет
Описание
Inclusion Criteria:
- Able to provide written informed consent voluntarily.
- Age ≥ 18 years old, any gender.
- Diagnosed with severe complicated intra-abdominal infection (cIAI) within 48 hours, consistent with the 2025 expert consensus for cIAI diagnosis. Diagnosis is confirmed by clinical symptoms (fever, abdominal pain, distension, etc.), abdominal imaging (CT/ultrasound/MRI), intraoperative findings, or positive pathogen culture of abdominal drainage fluid.
- Baseline Sequential Organ Failure Assessment (SOFA) score ≥ 2 points.
Exclusion Criteria:
- Severe immune deficiency conditions, including AIDS, prior solid organ or bone marrow transplantation, HIV infection with CD4 count < 200 cells/mm³, long-term high-dose glucocorticoid therapy (prednisone > 20 mg/day), ongoing chemotherapy for malignant tumors, or absolute neutrophil count < 1000 cells/mm³.
- Severe irreversible underlying diseases, including chronic renal failure requiring dialysis, Child-Pugh grade C liver disease, liver disease with severe portal hypertension, or acute liver failure.
- Patients with active malignant tumors, pregnancy, or severe psychiatric disorders.
- American Society of Anesthesiologists (ASA) physical status grade IV or above.
- Severe coagulation disorder defined as ISTH-DIC score ≥ 5 points.
- Critically ill patients with expected death within 48 hours after admission.
- Known allergy to ulinastatin or any ingredients of the study preparation.
- Any condition that, in the judgment of the principal investigator, makes the patient inappropriate for trial participation.
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Low-dose Ulinastatin
Intravenous infusion of ulinastatin 100,000 IU, three times daily for 5 consecutive days, diluted in 100 mL normal saline, administered on the basis of standardized routine treatment for complicated intra-abdominal infection.
|
Low dose:100000 IU iv tid×5d; High dose:300000 IU iv tid×5d, diluted in 100mL normal saline
|
|
Экспериментальный: High-dose Ulinastatin
Intravenous infusion of ulinastatin 300,000 IU, three times daily for 5 consecutive days, diluted in 100 mL normal saline, administered on the basis of identical standardized routine treatment.
|
Low dose:100000 IU iv tid×5d; High dose:300000 IU iv tid×5d, diluted in 100mL normal saline
|
|
Плацебо Компаратор: Normal Saline Placebo
Identical standard routine treatment.
Equal volume of 0.9% normal saline infused intravenously three times daily for 5 days as placebo.
Rescue high-dose ulinastatin can be given per investigator's judgment for treatment failure patients.
|
Equal-volume 0.9% normal saline iv tid×5d as placebo
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Mean change from baseline in Systemic Immune-Inflammation Index (SII) at Day 5
Временное ограничение: Baseline (before treatment), Day 5
|
The Systemic Immune-Inflammation Index (SII) is calculated from routine blood test results as platelet count multiplied by neutrophil count divided by lymphocyte count.
The mean change in SII values from baseline to Day 5 will be compared across the three groups to assess the immunomodulatory effect of ulinastatin on systemic immune-inflammatory status in patients with complicated intra-abdominal infection.
|
Baseline (before treatment), Day 5
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Mean change from baseline in Systemic Immune-Inflammation Index (SII) at 48 Hours
Временное ограничение: Baseline, 48 hours
|
The Systemic Immune-Inflammation Index (SII) is calculated from routine blood test results as platelet count multiplied by neutrophil count divided by lymphocyte count.
We will calculate the mean change in SII at 48 hours relative to baseline, and compare these changes among the three treatment groups to evaluate the sustained anti-inflammatory and immunomodulatory effects of ulinastatin.
|
Baseline, 48 hours
|
|
Mean change from baseline in C-reactive protein (CRP) at Day 1, Day 3, Day 5
Временное ограничение: Baseline, Day 1, Day 3, Day 5
|
Serum CRP levels will be measured at scheduled time points.
Changes from baseline will be compared among groups to evaluate inflammatory status.
|
Baseline, Day 1, Day 3, Day 5
|
|
Mean change from baseline in Interleukin-6 (IL-6) at Day 1, Day 3, Day 5
Временное ограничение: Baseline, Day 1, Day 3, Day 5
|
Serum IL-6 levels will be measured at scheduled time points.
Changes from baseline will be compared among groups to evaluate inflammatory status.
|
Baseline, Day 1, Day 3, Day 5
|
|
Mean change from baseline in CD4+ T cell count at Day 1, Day 3, Day 5
Временное ограничение: Baseline, Day 1, Day 3, Day 5
|
Peripheral CD4+ T cell count will be measured at scheduled time points.
Changes from baseline will be compared among groups.
|
Baseline, Day 1, Day 3, Day 5
|
|
Mean change from baseline in CD4+/CD8+ T cell ratio at Day 1, Day 3, Day 5
Временное ограничение: Baseline, Day 1, Day 3, Day 5
|
CD4+/CD8+ ratio will be calculated at scheduled time points.
Changes from baseline will be compared among groups.
|
Baseline, Day 1, Day 3, Day 5
|
|
Mean change from baseline in Sequential Organ Failure Assessment (SOFA) total score at Day 3, Day 5, Day 7
Временное ограничение: Baseline, Day 3, Day 5, Day 7
|
The full name of the scale is Sequential Organ Failure Assessment (SOFA) score.
The score ranges from a minimum of 0 to a maximum of 24.
Higher SOFA scores indicate worse organ dysfunction and poorer clinical outcomes.
SOFA scores will be assessed at baseline and follow-up time points.
Score changes will be compared to evaluate organ function improvement.
|
Baseline, Day 3, Day 5, Day 7
|
|
Cumulative incidence of new-onset organ failure at Day 7
Временное ограничение: Up to Day 7
|
New-onset organ failure is defined as an increase in the Sequential Organ Failure Assessment (SOFA) score of ≥2 points from baseline.
The cumulative incidence of new organ failure occurring within 7 days after treatment initiation will be calculated and compared across the three study groups.
|
Up to Day 7
|
|
Correlation coefficients between serial immune-inflammatory marker changes and 28-day all-cause mortality
Временное ограничение: Baseline, Day 1, Day 3, Day 5, up to Day 28
|
Serial dynamic values of systemic immune-inflammatory markers, including Systemic Immune-Inflammation Index (SII), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Lymphocyte-to-Monocyte Ratio (LMR), and CRP-to-Lymphocyte Ratio (CLR), will be collected from baseline to Day 5. Pearson correlation analysis will be performed to evaluate the correlation coefficients between dynamic changes of these markers and 28-day all-cause mortality.
|
Baseline, Day 1, Day 3, Day 5, up to Day 28
|
|
Proportion of participants with 28-day all-cause mortality
Временное ограничение: Up to Day 28
|
Vital status followed up to Day 28 after randomization.
The percentage of participants who die from any cause within 28 days will be reported and compared between groups.
|
Up to Day 28
|
|
Incidence of adverse events during treatment
Временное ограничение: From the start of intervention to 4 weeks after the last study drug administration
|
All adverse events and serious adverse events occurring during the treatment and follow-up period will be recorded in detail.
The incidence, severity and correlation with study drugs will be analyzed to evaluate the safety profile of ulinastatin.
|
From the start of intervention to 4 weeks after the last study drug administration
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Публикации и полезные ссылки
Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.
Общие публикации
- Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, Iyer S. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8. doi: 10.1007/s00134-014-3278-8. Epub 2014 Apr 16.
- Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, Saida L, Suker M, van der Harst E, Mieog JS, Bonsing BA, Klaver Y, Koerkamp BG, van Eijck CH. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study. Ann Surg. 2019 Jul;270(1):139-146. doi: 10.1097/SLA.0000000000002660.
- Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, Li L, Cao J, Xu F, Zhou Y, Guan CX, Jin SW, Deng J, Fang XM, Jiang JX, Zeng L. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Mil Med Res. 2022 Oct 9;9(1):56. doi: 10.1186/s40779-022-00422-y.
- Chen L, Jin S, Yang M, Gui C, Yuan Y, Dong G, Zeng W, Zeng J, Hu G, Qiao L, Wang J, Xi Y, Sun J, Wang N, Wang M, Xing L, Yang Y, Teng Y, Hou J, Bi Q, Cai H, Zhang G, Hong Y, Zhang Z. Integrated Single Cell and Bulk RNA-Seq Analysis Revealed Immunomodulatory Effects of Ulinastatin in Sepsis: A Multicenter Cohort Study. Front Immunol. 2022 May 11;13:882774. doi: 10.3389/fimmu.2022.882774. eCollection 2022.
- Lim YP, Bendelja K, Opal SM, Siryaporn E, Hixson DC, Palardy JE. Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis. J Infect Dis. 2003 Sep 15;188(6):919-26. doi: 10.1086/377642. Epub 2003 Aug 26.
- Feier CVI, Motoc A, Muntean C, Vonica RC, Gaborean V, Olariu S, Murariu MS. Systemic inflammatory indices and age-dependent severity in acute appendicitis: a retrospective cohort study. Front Immunol. 2025 Jul 15;16:1620459. doi: 10.3389/fimmu.2025.1620459. eCollection 2025.
- Nebelung H, Wotschel N, Held HC, Kirchberg J, Weitz J, Radosa CG, Laniado M, Hoffmann RT, Plodeck V. ICU patients with infectious complications after abdominopelvic surgery: Is thoracic CT in addition to abdominal CT helpful? Ann Intensive Care. 2023 Feb 10;13(1):6. doi: 10.1186/s13613-023-01104-1.
- Huston JM, Barie PS, Dellinger EP, Forrester JD, Duane TM, Tessier JM, Sawyer RG, Cainzos MA, Rasa K, Chipman JG, Kao LS, Pieracci FM, Colling KP, Heffernan DS, Lester J; Therapeutics and Guidelines Committee. The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection: 2024 Update. Surg Infect (Larchmt). 2024 Aug;25(6):419-435. doi: 10.1089/sur.2024.137. Epub 2024 Jul 11.
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования (Оцененный)
30 октября 2026 г.
Первичное завершение (Оцененный)
31 декабря 2027 г.
Завершение исследования (Оцененный)
30 июня 2028 г.
Даты регистрации исследования
Первый отправленный
3 июня 2026 г.
Впервые представлено, что соответствует критериям контроля качества
26 июня 2026 г.
Первый опубликованный (Действительный)
29 июня 2026 г.
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
29 июня 2026 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
26 июня 2026 г.
Последняя проверка
1 июня 2026 г.
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- FJXH-2026-0506
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
НЕТ
Описание плана IPD
Individual participant data (IPD) will not be made publicly available for this clinical trial.
Relevant study protocol, aggregate clinical outcome results, and summary analysis data may be published in peer-reviewed journals or presented at academic conferences after the completion of the trial.
Data access is restricted to the study research team only due to institutional and participant privacy requirements.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Нет
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Нет
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .